Pfizer

Pfizer’s dividend yields about 6.2%, one of the highest in the S&P 500, and its trailing 12‑month free cash flow of nearly $11 billion exceeds roughly $9.8 billion in cash dividends, supporting payout sustainability. The company is cutting expenses to strengthen finances as it navigates its next growth phase. By contrast, Eli Lilly offers minimal yield (~0.6%) but has delivered rapid dividend growth driven by strong GLP‑1 profits, making Lilly a growth-plus-income option while Pfizer suits yield-focused investors. » More on finance.yahoo.com

A largely redacted contract shows that Pfizer must hand over part of additional net revenues from higher drug prices abroad to the U.S. Department of Health and Human Services (HHS). The agreement runs from January 1, 2026, to January 20, 2029; the percentage rate, the drugs affected and the allocation of the funds are secret. Pfizer stresses its contribution to relieving U.S. patients, analysts view the deal as politically advantageous for the company, while other markets could be burdened by higher prices. » More on deraktionaer.de

CEO Albert Bourla says Pfizer has addressed tariff and pricing pressures and COVID product declines are less impactful, while the company has beaten EPS estimates in recent quarters. Pfizer reports $13 billion in annualized revenue from newer and acquired products and has cut about $7.2 billion in costs to help offset upcoming patent expirations. Major risks remain as Eliquis and Ibrance face U.S. patent cliffs in 2028 and 2027 respectively, but management expects oncology and weight‑loss programs plus other pipeline assets to deliver launches by the end of the decade. Pfizer maintains a high forward dividend yield (6.2%) and is likely to keep payouts intact while revenue may dip in the near term as patent losses are navigated. » More on finance.yahoo.com